Achaogen, Inc. has been awarded a contract for $1.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), with additional funding of as much as $3.0 million during the next three years if all options are exercised.   The contract will specifically fund the discovery and development of LpxC inhibitors, which are novel small molecule agents, for the treatment of bacterial infections, including those resistant to currently available antibiotics. Achaogen’s LpxC inh...